School of Chemistry, Sun Yat-sen University, Guangzhou 510006, China.
International Cooperative Laboratory of Traditional Chinese Medicine Modernization & Innovative Drug Development of Chinese Ministry of Education (MOE) & Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, China.
J Med Chem. 2024 Mar 14;67(5):3448-3466. doi: 10.1021/acs.jmedchem.3c01719. Epub 2024 Feb 14.
The aggregation of specific proteins is a histopathological hallmark in various neurodegenerative diseases (NDs), among which Alpha-synuclein (α-Syn) and tau have received increased attention. The targeted protein degradation (TPD) strategy has been studied in the treatment of NDs, but multitarget bifunctional molecules have been ignored. Herein, a series of effective dual PROTAC degraders were developed, which could degrade α-Syn aggregates and total tau simultaneously. The degradation effects were evaluated , and the results showed that could significantly knockdown α-Syn aggregates and total tau in the degradation efficiency with DC of 1.57 ± 0.55 and 4.09 ± 0.90 μM, respectively. Further mechanistic exploration showed that the degradation effect was mediated by the ubiquitin-proteasome system (UPS). Additionally, the therapeutic efficacy of was confirmed in an MPTP-induced PD mouse model. Our results suggest that these dual PROTACs may provide a potential therapeutic strategy for NDs.
特定蛋白质的聚集是各种神经退行性疾病(NDs)的组织病理学标志,其中α-突触核蛋白(α-Syn)和tau 受到了越来越多的关注。靶向蛋白降解(TPD)策略已被用于 NDs 的治疗研究,但多靶标双功能分子一直被忽视。本文开发了一系列有效的双 PROTAC 降解剂,可同时降解α-Syn 聚集物和总 tau。评估了降解效果,结果表明,化合物 可分别以 DC 值为 1.57 ± 0.55 和 4.09 ± 0.90 μM 显著下调 α-Syn 聚集物和总 tau。进一步的机制探索表明,降解作用是通过泛素-蛋白酶体系统(UPS)介导的。此外,在 MPTP 诱导的 PD 小鼠模型中证实了 的治疗效果。我们的研究结果表明,这些双 PROTAC 可能为 NDs 提供一种潜在的治疗策略。